Terumo (OTCMKTS:TRUMY) Shares Gap Down - Here's What Happened

Key Points

• Terumo Corp. shares gapped down from a previous close of $17.50 to open at $16.85, eventually trading at $16.91 with a volume of 1,047 shares.
• The company reported quarterly earnings of $0.20 per share, surpassing the consensus estimate of $0.17, but fell short on revenue with $1.76 billion against an expected $1.80 billion.
• Terumo has a low debt-to-equity ratio of 0.07, indicating strong financial health, alongside a market cap of $25.16 billion and a PE ratio of 29.81.

Shares of Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $17.50, but opened at $16.85. Terumo shares last traded at $16.91, with a volume of 1,047 shares trading hands.

Terumo Price Performance

The stock has a market cap of $25.16 billion, a PE ratio of 29.81 and a beta of 0.79. The company has a current ratio of 2.64, a quick ratio of 1.53 and a debt-to-equity ratio of 0.07. The company's 50 day moving average is $17.60 and its 200-day moving average is $18.21.

Terumo (OTCMKTS:TRUMY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.03. Terumo had a net margin of 12.09% and a return on equity of 9.19%. The firm had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.80 billion.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.